Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2949)	6/17/2010 3:31:53 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MYGN and the Univ. of Utah Research Foundation announced yesterday that they are appealing the decision rendered in March that found that the BRCA gene patents are "unpatentable.<g> Back in March, MYGN said that it planed to appeal the ruling, and noted that although the court invalidated the 15 challenged claims under the seven BRCA patents, Judge Sweet did not invalidate the 164 claims remaining under those seven patents nor the 16 additional patents covering MYGN's BRACAnalysis breast and ovarian cancer tests.<g> Although the court's ruling was specific to genes, the rationale could be extend to patents covering biological molecules, including peptides or siRNAs,according to some patent attorneys. The court essentially said that "if it exists in nature and you are isolating it, it's still a product of nature," Will see what the Appeals Court's rule will be on this interesting matter. <g> Bernard